ATE219683T1 - Verfahren und zubereitungen zur verzoegerung oder vorbeugung von autoimmun krankheiten - Google Patents

Verfahren und zubereitungen zur verzoegerung oder vorbeugung von autoimmun krankheiten

Info

Publication number
ATE219683T1
ATE219683T1 AT94914804T AT94914804T ATE219683T1 AT E219683 T1 ATE219683 T1 AT E219683T1 AT 94914804 T AT94914804 T AT 94914804T AT 94914804 T AT94914804 T AT 94914804T AT E219683 T1 ATE219683 T1 AT E219683T1
Authority
AT
Austria
Prior art keywords
autoimmune diseases
delaying
preparations
preventing autoimmune
methods useful
Prior art date
Application number
AT94914804T
Other languages
English (en)
Inventor
Noel K University Of Maclaren
Med P O Box Lab
Andrew Muir
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Application granted granted Critical
Publication of ATE219683T1 publication Critical patent/ATE219683T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94914804T 1993-04-16 1994-04-15 Verfahren und zubereitungen zur verzoegerung oder vorbeugung von autoimmun krankheiten ATE219683T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/048,979 US5891435A (en) 1993-04-16 1993-04-16 Methods and compositions for delaying or preventing the onset of autoimmune disease
PCT/US1994/004179 WO1994023737A1 (en) 1993-04-16 1994-04-15 Methods and compositions for delaying or preventing the onset of autoimmune disease

Publications (1)

Publication Number Publication Date
ATE219683T1 true ATE219683T1 (de) 2002-07-15

Family

ID=21957455

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94914804T ATE219683T1 (de) 1993-04-16 1994-04-15 Verfahren und zubereitungen zur verzoegerung oder vorbeugung von autoimmun krankheiten

Country Status (8)

Country Link
US (1) US5891435A (de)
EP (1) EP0693933B1 (de)
JP (1) JP3001638B2 (de)
AT (1) ATE219683T1 (de)
CA (1) CA2160543C (de)
DE (1) DE69430868T2 (de)
DK (1) DK0693933T3 (de)
WO (1) WO1994023737A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094597B1 (en) 1994-05-20 2006-08-22 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US5773570A (en) * 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
EP0835129B1 (de) * 1995-06-30 2003-10-29 Novo Nordisk A/S Vorbeugung einer krankheit mit diabetes charakter
US20020098194A1 (en) * 1996-03-21 2002-07-25 Paul V. Lehmann Methods for inducing immunity
EP1045860A2 (de) * 1998-01-08 2000-10-25 William Clifford Duckworth Verfahren und zusammensetzungen für die therapie und diagnose von mit insulin zusammenhängenden krankheiten
EP1094828A4 (de) * 1998-05-07 2005-01-26 Univ California Verwendung vernachlässigter gewebsspezifischer antigene zur modulation der immunantwort
US7030098B2 (en) 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
EP1168923B1 (de) * 1999-03-12 2005-11-02 The Board Of Trustees Of The Leland Stanford Junior University Dna-impfung zur behandlung von autoimmunerkrankungen
US6884785B2 (en) * 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
US20070259007A1 (en) * 1999-10-19 2007-11-08 Kruzel Marian L Lactoferrin: an adjuvant for vaccines
AU1600401A (en) * 1999-11-12 2001-06-06 Chinese University Of Hong Kong, The Malaria vaccine
US7608683B2 (en) * 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
BR0115246A (pt) 2000-11-01 2005-04-26 Univ California Peptìdeos imunomoduladores derivados de proteìnas de choque e seu uso
KR100729645B1 (ko) * 2000-12-29 2007-06-18 주식회사 녹십자홀딩스 글루타민산 데카르복실라제를 코딩하는 유전자가 삽입된재조합 백시니아 바이러스 및 이를 포함하는 제 1형당뇨병 예방 백신
US20030045467A1 (en) * 2001-01-05 2003-03-06 Tihamer Orban Autoantigen composition
WO2004098645A1 (en) * 2003-05-12 2004-11-18 Tolerogen, Ltd. Immunoglobulin conjugates of autoantigens and their use in the prevention of disease
WO2007127787A2 (en) * 2006-04-25 2007-11-08 Joslin Diabetes Center, Inc. Insulin autoantigen-specific regulatory cd4+ t cells
AU2007281911B2 (en) 2006-08-04 2014-02-06 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
US9821035B2 (en) 2012-08-22 2017-11-21 Regimmune Corporation Preparation for preventing or treating type I diabetes
EP3033106A1 (de) * 2013-08-14 2016-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunadjuvanzienzusammensetzungen und verwendungen davon
EP3274053A4 (de) * 2015-03-23 2018-12-05 The Brigham and Women's Hospital, Inc. Tolerogene nanopartikel zur behandlung von diabetes mellitus

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2051574B (en) * 1979-05-10 1984-01-18 Kyoto Pharma Ind Adjuvant for promoting absorption of pharmacologically active substances through the rectum
US4464363A (en) * 1979-12-20 1984-08-07 Merck & Co., Inc. Ajuvants for rectal delivery of drug substances
ZA808097B (en) * 1980-12-29 1982-01-27 Lilly Co Eli Novel insulin formulations
JPS58189121A (ja) * 1982-04-30 1983-11-04 Ajinomoto Co Inc インシユリン投与賦活剤
US4789660A (en) * 1987-09-10 1988-12-06 American Home Products Corporation Insulin administration using methyl and propyl paraben
SU1624511A1 (ru) * 1989-02-14 1991-01-30 Донецкий государственный медицинский институт им.М.Горького Способ моделировани сахарного диабета
CA2063414A1 (en) * 1989-06-19 1990-12-20 Richard A. Young Vector-mediated genomic insertion and expression of dna in bcg
FI920139A0 (fi) * 1989-07-14 1992-01-13 Autoimmune Inc Foerfaranden foer behandling och foerfindrande av autoimmun uveoretinitis hos daeggdjur.
HUT61896A (en) * 1990-03-02 1993-03-29 Autoimmune Inc Process for producing orally administrable pharmaceutical compositions comprising autoantigenes, suitable for improving down-control of autoimmune diseases
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
WO1994012529A1 (en) * 1992-12-03 1994-06-09 The Regents Of The University Of California Improved reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome
US5725860A (en) * 1994-03-07 1998-03-10 Auckland Uniservices Limited Method for reducing the risk of developing diabetes

Also Published As

Publication number Publication date
US5891435A (en) 1999-04-06
JP3001638B2 (ja) 2000-01-24
JPH08508036A (ja) 1996-08-27
EP0693933B1 (de) 2002-06-26
DE69430868T2 (de) 2003-01-30
DK0693933T3 (da) 2002-10-21
EP0693933A1 (de) 1996-01-31
CA2160543A1 (en) 1994-10-27
DE69430868D1 (de) 2002-08-01
CA2160543C (en) 2002-07-30
WO1994023737A1 (en) 1994-10-27

Similar Documents

Publication Publication Date Title
DE69430868D1 (de) Verfahren und zubereitungen zur verzoegerung oder vorbeugung von autoimmun krankheiten
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
AP2000001888A0 (en) Method for treatment of diabetes using peptides analogues of insulin.
DE69521796D1 (de) Behandlung des partiellen wachstumshormon-unempfindlichkeitssyndromes
WO1995025749A3 (en) Eating suppressant peptides
ATE127345T1 (de) Stressproteine und verwendungen dafür.
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
KR970706842A (ko) 아실화된 인슐린 동족체(Acylated Insulin Analogs)
EP0342860A3 (de) Neues Protein, Sequenze mit enthaltendem Gene, Vektoren, Verfahren zur Herstellung und Verwendung
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
NO952336L (no) Insulin analoger
AU684317B2 (en) Coccidiosis poultry vaccine
ZA846191B (en) Antigens and monoclonal antibodies reactive against sporozoites of eimeria spp
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
AU612683B2 (en) Synthetic peptides, antibodies directed against them, and the use thereof
AU5628796A (en) Coccidiosis poultry vaccine
EP0770624A3 (de) Peptid das eine Immunantwort gegen menschlichen Magenkrebs induziert und Arzneimittel die es enthält zur Vorbeugung oder Behandlung von Magenkrebs
NZ221379A (en) Nematode plasma membrane-associated protein, extraction method and vaccines containing it
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
AU3172095A (en) Coccidiosis poultry vaccine
DK0378432T3 (da) Peptider, deres anvendelse til inhibering af modningen af T-lymfocytter og aktiviteten af makrofager samt fremgangsmåder til deres fremstilling
GR3001922T3 (en) Use of n,n'-bis-l-amino acid-l-cystin peptides in amino acid preparations for oral and parenteral administration

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee